IQWiG

Drug assessment at a glance: A26-59[1]

Blinatumomab (B-ALL, first and second complete remission)

6 November 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-59. The GBA decides on the added benefit.

Research question 1 of the benefit assessment

Population	Adults with Ph- CD19+ B-cell precursor ALL in first complete remission with MRD of at least 0.1%
Intervention	blinatumomab
Comparator	Individualised treatment, selecting from: ▪ hyperfractionated cyclophosphamide in combination with cytarabine, dexamethasone, doxorubicin, methotrexate and vincristine ▪ cyclophosphamide in combination with cytarabine, daunorubicin, dexamethasone, methotrexate, pegaspargase, prednisone, thioguanine and vincristine ▪ cyclophosphamide in combination with cytarabine, dexamethasone, doxorubicin, mercaptopurine, pegaspargase, thioguanine and vincristine ▪ cyclophosphamide in combination with cytarabine, dexamethasone, doxorubicin, mercaptopurine and vincristine ▪ cyclophosphamide in combination with cytarabine, mercaptopurine, pegaspargase and vincristine ▪ cytarabine in combination with methotrexate and pegaspargase ▪ dexamethasone in combination with doxorubicin, mercaptopurine, methotrexate, pegaspargase and vincristine ▪ mercaptopurine in combination with methotrexate, prednisone and vincristine ▪ prednisone in combination with vincristine
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects – research question 1

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects – research question 1

- No suitable data were available.

Research question 2 of the benefit assessment

Population	Adults with Ph- CD19+ B-cell precursor ALL in second complete remission with MRD of at least 0.1%
Intervention	blinatumomab
Comparator	Individualised treatment, selecting from: ▪ hyperfractionated cyclophosphamide in combination with cytarabine, dexamethasone, doxorubicin, methotrexate and vincristine ▪ hyperfractionated cyclophosphamide in combination with cytarabine, dexamethasone, doxorubicin, methotrexate, vincristine and pegaspargase ▪ cyclophosphamide in combination with dexamethasone and vincristine ▪ cyclophosphamide in combination with dexamethasone, doxorubicin and vincristine ▪ cyclophosphamide in combination with daunorubicin, prednisone, pegaspargase and vincristine ▪ cyclophosphamide in combination with cytarabine, daunorubicin, dexamethasone, mercaptopurine, pegaspargase and vincristine ▪ cyclophosphamide in combination with cytarabine, daunorubicin, mercaptopurine, pegaspargase, prednisone and vincristine ▪ dexamethasone in combination with doxorubicin, methotrexate, pegaspargase and vincristine ▪ mercaptopurine in combination with methotrexate, prednisone and vincristine ▪ methotrexate in combination with dexamethasone, pegaspargase and vincristine ▪ prednisone in combination with vincristine ▪ tisagenlecleucel ▪ brexucabtagene autoleucel
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects – research question 2

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects – research question 2

- No suitable data were available.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Blinatumomab (B-ALL, 1. und 2. Komplettremission); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 03.11.2026]. URL: https://doi.org/10.60584/A26-59.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, MRD-positiv, Erwachsene) [online]. 2026 [Accessed: 03.11.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1349/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-59.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de